Skip to content
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Gastroenterology

What Is Life Expectancy With Familial Adenomatous Polyposis?

At a Glance

For people with classic familial adenomatous polyposis, timely preventive colon surgery and lifelong specialist surveillance can make life expectancy near normal. Surgery greatly lowers colorectal cancer risk, but ongoing screening is still needed for polyps and tumors elsewhere.

With proactive medical care—specifically, timely preventative surgery and lifelong surveillance—the life expectancy for someone with classic Familial Adenomatous Polyposis (FAP) can be near normal [1].

Because classic FAP carries a near-100% lifetime risk of developing colorectal cancer without appropriate treatment [2] [3] [4], the decision to undergo preventative surgery fundamentally changes the disease’s outlook. It replaces a near-certain, premature cancer diagnosis with the opportunity for a long life [5]. However, it is important to understand that “near-normal life expectancy” is a statistical outlook, not an individual guarantee, and it does not mean an unaffected life. You will still need lifelong specialist care to monitor for other FAP-related risks and to manage the impacts of surgery on your daily routine.

The Impact of Preventative Surgery

In classic FAP, hundreds or thousands of polyps typically begin forming in the colon and rectum during adolescence [3] [6]. Without prophylactic (preventative) surgery, these polyps inevitably progress to colorectal cancer, often by age 40 [2] [4]. (Note: Attenuated FAP, a milder form of the condition, involves fewer polyps and a later, though still elevated, cancer risk).

Data from national patient registries shows exactly how much preventative care improves survival:

  • Symptom-diagnosed: Historically, patients in a Danish registry who were diagnosed only after developing FAP symptoms had a median life expectancy of approximately 55 years [7].
  • Proactively screened: In contrast, patients identified early through family screening programs had a median life expectancy of 72 years—much closer to the general population [7].

Another study observing patients who had undergone preventative colon surgery and maintained their follow-up care reported an approximately 99% overall survival rate at 15 years [8]. These cohort statistics demonstrate the profound benefit of preventative care, though your individual outlook depends on your specific genetic mutation, whether cancer was present before surgery, and your adherence to lifelong screening.

Shifting Focus: Health Risks After Surgery

It is a common misconception that removing the colon cures FAP. While prophylactic surgery greatly reduces your risk of colorectal cancer, it does not eliminate it entirely, and your body retains a genetic predisposition to form growths in other areas [9] [10]. Staying ahead of these risks is the key to protecting your long-term health.

1. Upper Gastrointestinal Polyps and Cancer

After preventative colon surgery, cancers of the upper digestive tract—specifically in the duodenum (the first part of the small intestine) and the ampulla (where bile and pancreatic ducts enter the intestine)—become major health risks [9] [10].

  • Polyps frequently develop in these areas [11]. While stomach polyps also occur, the risk of stomach cancer varies depending on your population and specific gastric findings.
  • To manage these risks, you will need regular upper endoscopies. Your screening interval is usually determined by your Spigelman stage, a scoring system that evaluates the number, size, and microscopic features (histology and dysplasia) of your duodenal polyps [12] [13].

2. Desmoid Tumors

A desmoid tumor is a non-cancerous mass of fibrous tissue that can grow in the abdomen. Because they do not spread (metastasize) to other organs, they are not cancer, but they can grow aggressively, pressing on organs or blood vessels and causing severe pain or bowel blockages [14].

  • Desmoids can occur at any time, but abdominal surgery is a known trigger. Your lifetime risk is heavily influenced by your specific APC gene variant, family history, and sex [15] [16].
  • Contact your care team promptly if you experience a new or enlarging abdominal mass, persistent abdominal pain, vomiting, or unexplained swelling. Management requires a specialized, multidisciplinary team, as many desmoids can be safely observed or treated with medication rather than rushing to more surgery [14] [17].

3. Rectal Remnant or Pouch Polyps

Preventative surgery usually involves either an ileorectal anastomosis (IRA) (which leaves the rectum intact) or an ileal pouch-anal anastomosis (IPAA) (which removes the rectum but uses the small intestine to create a “J-pouch,” leaving a small anal transition zone).

  • Polyps can still grow in your retained rectum or your J-pouch [18] [19].
  • You will require lifelong lower endoscopies to monitor these tissues. The frequency of these scopes depends on your surgical anatomy, polyp burden, and your doctor’s guidelines [18] [19].

4. Other Extraintestinal Risks

FAP is associated with an increased risk for other issues, including thyroid cancer [20] [21]. Your genetics team will recommend periodic physical examinations or ultrasounds to monitor your thyroid and other relevant organs based on current guidelines.

Life Beyond the Numbers

While modern medicine makes a normal lifespan possible, FAP and its treatments still impact your quality of life. Prophylactic surgeries can permanently alter your bowel frequency, continence, and fertility, and the anxiety of lifelong medical surveillance is a heavy burden. Working closely with a dedicated hereditary-cancer registry and seeking out supportive care can help you navigate both the physical and emotional realities of a long life with FAP.

Common questions in this guide

What is the life expectancy for someone with classic FAP after treatment?
With timely preventive surgery and lifelong specialist surveillance, life expectancy for someone with classic FAP can be near normal. This is a population-level outlook rather than a guarantee, and individual outcomes depend on factors such as the APC variant, whether cancer was present before surgery, and follow-up care.
Why does preventive surgery improve the outlook for FAP?
Classic FAP causes large numbers of colon and rectal polyps that have a near-certain lifetime risk of becoming colorectal cancer without appropriate treatment. Removing the at-risk bowel greatly reduces that cancer risk and gives people the opportunity for a longer life, although it does not eliminate the need for ongoing care.
Can FAP still cause health problems after the colon is removed?
Yes. FAP can continue to cause polyps in the upper digestive tract, a retained rectum or surgical pouch, and sometimes the thyroid, while desmoid tumors can develop in the abdomen. Lifelong endoscopies, examinations, and other recommended surveillance are needed to find and manage these problems early.
How does my type of FAP surgery affect lifelong follow-up?
An ileorectal anastomosis leaves the rectum in place, while an ileal pouch-anal anastomosis removes the rectum and creates a pouch from the small intestine. Polyps can develop in either the retained rectum or the pouch, so the required lower endoscopy schedule depends on your anatomy and polyp burden.
What is Spigelman staging, and why does it matter?
Spigelman staging is a scoring system for polyps in the duodenum, the first part of the small intestine. It considers the number and size of polyps and their microscopic features, and the resulting stage helps determine how often upper endoscopy is needed.
Which symptoms should prompt someone with FAP to call the care team?
A new or enlarging abdominal mass, persistent abdominal pain, vomiting, or unexplained swelling should be reported promptly. These symptoms can occur with desmoid tumors or bowel blockage and should not wait until the next routine scan.

Get notified when new evidence is published on Familial Adenomatous Polyposis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (21)
  1. 1

    Management of familial adenomatous polyposis and MUTYH-associated polyposis; new insights.

    Aelvoet AS, Buttitta F, Ricciardiello L, Dekker E

    Best practice & research. Clinical gastroenterology 2022; (58-59()):101793 doi:10.1016/j.bpg.2022.101793.

    PMID: 35988966
  2. 2

    Colorectal family polyadenomatous diseases. What management in 2020?

    Menahem B, Alves A, Regimbeau JM, Sabbagh C

    Journal of visceral surgery 2020; (157(2)):127-135 doi:10.1016/j.jviscsurg.2019.12.003.

    PMID: 32113818
  3. 3

    Familial adenomatous polyposis in pediatrics: natural history, emerging surveillance and management protocols, chemopreventive strategies, and areas of ongoing debate.

    Septer S, Lawson CE, Anant S, Attard T

    Familial cancer 2016; (15(3)):477-85 doi:10.1007/s10689-016-9905-5.

    PMID: 27056662
  4. 4

    The importance of genetics for timing and extent of surgery in inherited colorectal cancer syndromes.

    Aoun RJN, Kalady MF

    Surgical oncology 2022; (43()):101765 doi:10.1016/j.suronc.2022.101765.

    PMID: 35643746
  5. 5

    Adenomatous Polyposis Syndromes: Diagnosis and Management.

    Mitchem JB, Hall JF

    Clinics in colon and rectal surgery 2016; (29(4)):321-329 doi:10.1055/s-0036-1584089.

    PMID: 31777463
  6. 6

    Familial adenomatous polyposis: a case study.

    Yorke J, Yamoah FA, Awoonor-Williams R, et al.

    Journal of surgical case reports 2020; (2020(10)):rjaa367 doi:10.1093/jscr/rjaa367.

    PMID: 33133502
  7. 7

    Colorectal Cancer in Individuals With Familial Adenomatous Polyposis, Based on Analysis of the Danish Polyposis Registry.

    Karstensen JG, Burisch J, Pommergaard HC, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2019; (17(11)):2294-2300.e1 doi:10.1016/j.cgh.2019.02.008.

    PMID: 30743005
  8. 8

    Prophylactic colectomy and rectal preservation in FAP: systematic endoscopic follow-up and adenoma destruction changes natural history of polyposis.

    Pasquer A, Benech N, Pioche M, et al.

    Endoscopy international open 2021; (9(7)):E1014-E1022 doi:10.1055/a-1467-6257.

    PMID: 34222624
  9. 9

    Cancer Incidence and Mortality in Familial Adenomatous Polyposis Syndrome.

    Feldman D, Rodgers-Fouche LH, Ukaegbu C, et al.

    Diseases of the colon and rectum 2025; (68(5)):531-543 doi:10.1097/DCR.0000000000003645.

    PMID: 39932215
  10. 10

    Extracolonic cancer risk in Dutch patients with APC (adenomatous polyposis coli)-associated polyposis.

    Ghorbanoghli Z, Bastiaansen BA, Langers AM, et al.

    Journal of medical genetics 2018; (55(1)):11-14 doi:10.1136/jmedgenet-2017-104545.

    PMID: 28490611
  11. 11

    Clinical features and distribution of the APC variant in duodenal and ampullary polyps in patients with familial adenomatous polyposis: a multicenter retrospective cohort study in Japan.

    Miyakura Y, Yamaguchi T, Lefor AK, et al.

    International journal of clinical oncology 2024; (29(2)):169-178 doi:10.1007/s10147-023-02442-7.

    PMID: 38142452
  12. 12

    Endoscopic management of duodenal adenomatosis in familial adenomatous polyposis-A case-based review.

    Soons E, Bisseling TM, van Kouwen MCA, et al.

    United European gastroenterology journal 2021; (9(4)):461-468 doi:10.1002/ueg2.12071.

    PMID: 34529357
  13. 13

    Endoscopic Management and Surgical Considerations for Familial Adenomatous Polyposis.

    Stanich PP, Sullivan B, Kim AC, Kalady MF

    Gastrointestinal endoscopy clinics of North America 2022; (32(1)):113-130 doi:10.1016/j.giec.2021.08.007.

    PMID: 34798980
  14. 14

    Desmoid Tumors in Familial Adenomatous Polyposis Patients: Favorable Outcomes with Multidisciplinary Management.

    Al-Sukhni E, Shapiro J, Suraweera H, et al.

    Annals of surgical oncology 2023; (30(8)):5142-5149 doi:10.1245/s10434-023-13675-1.

    PMID: 37237094
  15. 15

    Comparison of the outcomes of ileal pouch-anal anastomosis and ileorectal anastomosis for patients with familial adenomatous polyposis: a systematic review and meta-analysis.

    Tang PM, Vo BTN, Chang TC, et al.

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2026; (30(10)):102512 doi:10.1016/j.gassur.2026.102512.

    PMID: 42594997
  16. 16

    Familial adenomatous polyposis-associated desmoid disease: comprehensive review.

    Zare B, Clark S, Dileo P, et al.

    BJS open 2026; (10(5)) doi:10.1093/bjsopen/zrag089.

    PMID: 42808355
  17. 17

    Defining absolute postoperative desmoid risk in familial adenomatous polyposis according to APC genotype and family history: retrospective cohort study.

    Zare B, Bahar M, Clark S, Latchford A

    BJS open 2026; (10(5)) doi:10.1093/bjsopen/zrag090.

    PMID: 42765567
  18. 18

    Endoscopic management of patients with familial adenomatous polyposis after prophylactic colectomy or restorative proctocolectomy - systematic review of the literature.

    Gavric A, Sanchez LR, Brunori A, et al.

    Radiology and oncology 2024; (58(2)):153-169 doi:10.2478/raon-2024-0029.

    PMID: 38860690
  19. 19

    Patterns of Adenoma Recurrence in Familial Adenomatous Polyposis Patients after Ileal Pouch-Anal Anastomosis.

    Goldstein AL, Kariv R, Klausner JM, Tulchinsky H

    Digestive surgery 2015; (32(6)):421-5 doi:10.1159/000439143.

    PMID: 26360376
  20. 20

    Incidence of Cancer in Patients With Familial Adenomatous Polyposis in the Netherlands: A Nationwide Cohort Study.

    Bouchiba H, Aelvoet AS, van Kouwen MCA, et al.

    Gastroenterology 2026; (170(5)):942-952 doi:10.1053/j.gastro.2025.10.029.

    PMID: 41739006
  21. 21

    Updated European guidelines for clinical management of familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), gastric adenocarcinoma, proximal polyposis of the stomach (GAPPS) and other rare adenomatous polyposis syndromes: a joint EHTG-ESCP revision.

    Zaffaroni G, Mannucci A, Koskenvuo L, et al.

    The British journal of surgery 2024; (111(5)) doi:10.1093/bjs/znae070.

    PMID: 38722804

This page explains how preventive surgery and lifelong surveillance may affect life expectancy in FAP for informational purposes only and does not replace individualized medical advice. Discuss your outlook and screening plan with your hereditary-cancer care team.